Health · 1 sources covering this

STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care

Oura, the smart ring maker that recently delayed plans to go public, said it will pay $625 million to acquire Counsel Health, a clinical AI startup.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
Oura, the smart ring maker that recently delayed plans to go public, said it will pay $625 million to acquire Counsel Health, a clinical AI startup.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/0417a1a3bf41e307fa02e15347fe253ee7723c10"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care"></iframe>

STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care

How 1 sources are covering this

STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care

More from Health

STAT+: Men’s use of chatbots for therapy, and earnings season highlights

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care

More from Health

STAT+: Men&#8217;s use of chatbots for therapy, and earnings season highlights

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

STAT+: Pharmalittle: We&#8217;re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more

STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug

Reader

Trust & legal

Across the network

STAT+: Men’s use of chatbots for therapy, and earnings season highlights

STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more